From: Prescription characteristics of phosphate binders in a high pill burden for hemodialysis patients
Prescription | Patients | Total pill burden | Pill burden from all PBs | Pill burden from Ca-based PB | Pill burden from non-Ca-based PBs | |||||
---|---|---|---|---|---|---|---|---|---|---|
yes/no | n (%) | pills/day/patient | (P) | pills/day/patient | (P) | pills/day/patient | (P) | pills/day/patient | (P) | |
Oral calcimimetics | Non-user | 378 (70.9) | 13.9 ± 6.7 | < 0.001 | 5.77 ± 4.13 | < 0.001 | 4.03 ± 1.91 | < 0.001 | 4.49 ± 2.87 | 0.020 |
(evocalcet) | User | 155 (29.1) | 17.8 ± 8.7 | 7.80 ± 5.66 | 5.05 ± 2.06 | 5.75 ± 4.29 | ||||
IV caclimimetics | Non-user | 462 (86.7) | 14.8 ± 7.6 | 0.005 | 6.26 ± 4.74 | 0.040 | 4.29 ± 2.03 | 0.074 | 4.87 ± 3.54 | 0.209 |
(etelcalcetide HCl) | User | 71 (13.3) | 16.9 ± 7.0 | 7.43 ± 4.92 | 4.79 ± 1.84 | 5.31 ± 3.31 | ||||
Oral VDRAs | Non-user | 392 (73.5) | 15.4 ± 8.0 | 0.208 | 6.81 ± 4.96 | 0.001 | 4.57 ± 1.98 | < 0.001 | 5.00 ± 3.69 | 0.701 |
(calcitriol, alfacalcidol) | User | 141 (26.5) | 14.1 ± 6.3 | 5.36 ± 4.08 | 3.68 ± 1.98 | 4.78 ± 2.82 | ||||
IV VDRAs | Non-user | 245 (46.0) | 14.6 ± 7.2 | 0.360 | 6.12 ± 4.70 | 0.088 | 4.16 ± 2.11 | 0.054 | 5.06 ± 3.31 | 0.476 |
(calcitriol, maxacalcitol) | User | 288 (54.0) | 15.4 ± 7.9 | 6.68 ± 4.84 | 4.52 ± 1.93 | 4.88 ± 3.62 |